about
Economic considerations in the management of Alzheimer's diseaseHuperzine A for mild cognitive impairmentHuperzine A for Alzheimer's diseaseCurrent pharmacologic options for patients with Alzheimer's diseaseRational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysisStroke, dementia, and drug deliveryEquity in the new NHS: hard lessons from implementing a local healthcare policy on donepezilEvidence-based ethics--what it should be and what it shouldn't.Update on the pharmacological treatment of Alzheimer's diseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.Cholinergic modulation of working memory activity in primate prefrontal cortex.Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Cautionary tales in the clinical interpretation of therapeutic trial reports.Mechanisms generating dual-component nicotinic EPSCs in cortical interneuronsProlonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.Treatment of Alzheimer's disease across the spectrum of severity.A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapyEthanolic Extract of the Seed of Zizyphus jujuba var. spinosa Ameliorates Cognitive Impairment Induced by Cholinergic Blockade in Mice.Disease-modifying drugs in Alzheimer's disease.Dimebolin in dementia.Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.Increased hippocampal CA1 density of serotonergic terminals in a triple transgenic mouse model of Alzheimer's disease: an ultrastructural study.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Studies on interaction of buffalo brain cystatin with donepezil: an Alzheimer's drugDifferential expression of Homer1a in the hippocampus and cortex likely plays a role in radiation-induced brain injuryTreatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia.Tense prescriptions? Alzheimer medications and the anthropology of uncertainty.Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
P2860
Q22241448-664C9601-D6F7-4E9A-8B6E-5A8769958CDDQ24202101-CF488509-D1CD-44D3-8AAA-8CCC38CD671FQ24245024-4D91627B-D2B9-4985-BD86-4FC7966C265CQ24800530-3BEFDA12-E9DF-4D9A-B9A4-4F118DC88719Q24805169-9BBA7341-A58E-4820-9E0E-0DA83801CF09Q28166505-02BFF960-7E36-462A-B5FD-753905DC1557Q28344938-DA3C2E03-400B-471D-8013-51ACA3088026Q33378223-F06F43D7-4FEB-4F53-A2B4-A7BB85BC3208Q33836947-E11C4B18-9A81-42FD-9932-FDE34620AB1DQ33912750-6A82902E-28F9-4673-98D5-85C8801A2D5EQ34343927-B4B3CB00-160D-48A4-BC4F-3C0B492DB944Q34409349-01205C35-8EC6-4A0F-BD1D-181972978363Q34683821-E1C7EF3F-43F5-47F7-9A6F-AA266DE21DD7Q34762064-43DB6627-19E6-47DB-B484-A36B780EED8DQ35276747-6EFC2380-4EE7-44C0-B301-10D999310E6EQ35543969-7253912B-C309-4157-A5A1-57450700679FQ35748293-1AF70DC1-CD47-4A62-9580-C9070F3F76FFQ35876403-92A7686A-5BA9-4473-B535-DACAF45EE802Q36278143-20AA248F-2417-4B9D-8F9A-AA7A588811E4Q36474829-08D4C7E5-DCCE-4C5F-B97F-946637081CAFQ36842150-BC069ED8-236F-463D-9120-5F1538A3689FQ37017375-E9E8DF1E-60FD-4730-94B0-18A06D87F741Q37060223-F127D541-3F70-4E54-84B1-95EAA92D8896Q37286287-DA03F2BA-A825-4AC3-9E72-C7D1018BD47FQ37390739-CB69576E-769D-4229-A317-5B5AC292FBFCQ37765630-94356D52-705C-4523-951F-9AAE8F0EB6A9Q38149130-3617A124-4441-4BC2-9F6D-C6519B89CC05Q38626337-08A9AB42-1B0A-456B-8B1C-67EA1AE5FEDBQ38661735-A799E088-3C63-4486-ACD8-72A780168FB8Q39415447-E069D26C-21A9-4912-AEC6-CFD14CFD17ABQ42591784-C1BC4810-9210-4A25-B973-A4CA7E8D636BQ42762704-B4E25F5E-DD64-45F6-93BE-5B29A8AB3CFCQ47141950-7BAFFF7A-A33E-456B-BBD4-862602B442A7Q47609708-804F34C9-DA40-4378-B2AF-6B51A2D86293Q58698874-C06460CE-9C07-412D-B6BE-ABF640267E18
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Donepezil for dementia due to Alzheimer's disease
@ast
Donepezil for dementia due to Alzheimer's disease
@en
Donepezil for dementia due to Alzheimer's disease
@en-gb
Donepezil for dementia due to Alzheimer's disease
@nl
type
label
Donepezil for dementia due to Alzheimer's disease
@ast
Donepezil for dementia due to Alzheimer's disease
@en
Donepezil for dementia due to Alzheimer's disease
@en-gb
Donepezil for dementia due to Alzheimer's disease
@nl
altLabel
Donepezil for dementia due to Alzheimer's disease.
@en
prefLabel
Donepezil for dementia due to Alzheimer's disease
@ast
Donepezil for dementia due to Alzheimer's disease
@en
Donepezil for dementia due to Alzheimer's disease
@en-gb
Donepezil for dementia due to Alzheimer's disease
@nl
P2093
P2860
P1476
Donepezil for dementia due to Alzheimer's disease
@en
Donepezil for dementia due to Alzheimer's disease.
@en
P2093
P2860
P304
P356
10.1002/14651858.CD001190
P577
2003-01-01T00:00:00Z
2003-07-21T00:00:00Z